These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15550585)

  • 61. [Hodgkin lymphoma in Chile: experience of the national adult cancer program].
    Cabrera ME; García H; Lois V; León A; Peña K; Rossle A; Cerda B; Rojas H; Meneses P; Merino C; Aspillaga A; Vittini de C; Oliva J; Hales C; Rosas J;
    Rev Med Chil; 2007 Mar; 135(3):341-50. PubMed ID: 17505580
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
    Radford J; Illidge T; Counsell N; Hancock B; Pettengell R; Johnson P; Wimperis J; Culligan D; Popova B; Smith P; McMillan A; Brownell A; Kruger A; Lister A; Hoskin P; O'Doherty M; Barrington S
    N Engl J Med; 2015 Apr; 372(17):1598-607. PubMed ID: 25901426
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.
    Noordijk EM; Carde P; Dupouy N; Hagenbeek A; Krol AD; Kluin-Nelemans JC; Tirelli U; Monconduit M; Thomas J; Eghbali H; Aleman BM; Bosq J; Vovk M; Verschueren TA; Pény AM; Girinsky T; Raemaekers JM; Henry-Amar M
    J Clin Oncol; 2006 Jul; 24(19):3128-35. PubMed ID: 16754934
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.
    Cullen MH; Stuart NS; Woodroffe C; Murphy A; Fletcher J; Blackledge GR; Child JA; Grieve RJ; Jones EL
    J Clin Oncol; 1994 Apr; 12(4):779-87. PubMed ID: 7512132
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
    Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
    Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
    Delwail V; Jais JP; Colonna P; Andrieu JM
    Br J Haematol; 2002 Jul; 118(1):189-94. PubMed ID: 12100147
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity.
    Brusamolino E; Lunghi F; Orlandi E; Astori C; Passamonti F; Baraté C; Pagnucco G; Baio A; Franchini P; Lazzarino M; Bernasconi C
    Haematologica; 2000 Oct; 85(10):1032-9. PubMed ID: 11025593
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease.
    Santoro A; Bonfante V; Bonadonna G
    Ann Intern Med; 1982 Feb; 96(2):139-43. PubMed ID: 6174060
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).
    Straus DJ; Myers J; Koziner B; Lee BJ; Clarkson BD
    Cancer Chemother Pharmacol; 1983; 11(2):80-5. PubMed ID: 6194913
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
    N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.
    Karmiris TD; Grigoriou E; Tsantekidou M; Spanou E; Mihalakeas H; Baltadakis J; Apostolidis J; Pagoni M; Karakasis D; Bakiri M; Mitsouli C; Harhalakis N; Nikiforakis E
    Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.
    Lester EP; Petroni GR; Barcos M; Johnson JL; Millard FE; Cooper MR; Omura GA; Frei E; Peterson BA
    Cancer Invest; 2001; 19(5):447-58. PubMed ID: 11458812
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G; Santoro A; Bonfante V; Valagussa P
    Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II and IIIA).
    André M; Brice P; Cazals D; Hennequin C; Fermé C; Kerneis Y; Rousselot P; Zini JM; Lepage E; Gisselbrecht C
    Hematol Cell Ther; 1997 Apr; 39(2):59-65. PubMed ID: 9168301
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
    Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
    Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
    Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
    J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.